Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency

Remy S Petersen; Lauré M Fijen; Laurens E Franssen; Josephine M I Vos; Danny M Cohn

doi:10.1016/j.jacig.2024.100322

Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency

J Allergy Clin Immunol Glob. 2024 Aug 5;3(4):100322. doi: 10.1016/j.jacig.2024.100322. eCollection 2024 Nov.

Authors

Remy S Petersen¹, Lauré M Fijen¹, Laurens E Franssen², Josephine M I Vos^{3

4}, Danny M Cohn¹

Affiliations

¹ Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
³ Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
⁴ Department of Hematology, Cancer Center Amsterdam and Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Abstract

Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

Keywords: Acquired C1-inhibitor deficiency; MGUS; angioedema; bradykinin; daratumumab; monoclonal gammopathy.

Publication types

Case Reports